EP1341549A2 - Combination therapy for estrogen-dependent disorders - Google Patents
Combination therapy for estrogen-dependent disordersInfo
- Publication number
- EP1341549A2 EP1341549A2 EP01990699A EP01990699A EP1341549A2 EP 1341549 A2 EP1341549 A2 EP 1341549A2 EP 01990699 A EP01990699 A EP 01990699A EP 01990699 A EP01990699 A EP 01990699A EP 1341549 A2 EP1341549 A2 EP 1341549A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- cancer
- aromatase inhibitor
- lhrh agonist
- triptorelin
- exemestane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Definitions
- the present invention relates to a combination therapy for treating estrogen dependent cancers in susceptible mammals, including humans, comprising the steps of inhibiting hormone output of their testis or ovaries, respectively, and administering to said mammal at least one aromatase inhibitor.
- LHRH agonists Luteinizing Hormone Releasing Hormone agonists
- U.S. Pat. No. 4,775,660 relates to the treatment of female breast cancer by use of a combination therapy comprising administering an antiandrogen and an antiestrogen to a female after the hormone output of her ovaries has been blocked by chemical or surgical means.
- U.S. Pat. No. 4,775,661 relates to the treatment of female breast cancer by use of a therapy comprising administering to a female, after the hormone output of her ovaries has been blocked by chemical or surgical means, an antiandrogen and optionally an inhibitor of sex steroid biosynthesis.
- U.S. Pat. No. 4,760,053 describes the treatment of selected sex steroid dependent cancers which combines a LHRH agonist and/or an antiandrogen and/or an antiestrogen and/or at least one inhibitor of sex steroid biosynthesis.
- prostatic adenocarcinoma, benign prostatic hypertrophy and hormone-dependent mammary tumors may be treated with various LH-RH agonists and that prostate adenocarcinoma and benign hypertrophy may be treated by use of various LHRH agonists and an antiandrogen.
- U.S. Pat. No. 5,550,107 relates to a treatment of female breast and endometrial cancer by use of a therapy comprising administering to a female after the hormone output of the ovaries has been blocked an antiestrogen and at least one compound selected, e.g., from an androgen, a progestin, at least one inhibitor of sex steroid biosynthesis and one inhibitor of prolactin secretion.
- a therapy comprising administering to a female after the hormone output of the ovaries has been blocked an antiestrogen and at least one compound selected, e.g., from an androgen, a progestin, at least one inhibitor of sex steroid biosynthesis and one inhibitor of prolactin secretion.
- the invention provides a method for treating an sex-steroid dependent cancer in a mammal in need of such treatment, including humans, comprising administering simultaneously, separately or sequentially to said mammal an aromatase inhibitor and a
- LHRH agonist or antagonist in amounts and close in time sufficient to achieve a therapeutically useful effect, and wherein, when the cancer is breast cancer, and a) the LHRH agonist is triptorelin, then the aromatase inhibitor is other than formestane, b) the LHRH agonist is goserelin, then the aromatase inhibitor is other than vorozole or formestane, or c) the
- LHRH agonist is leuprorelin, then the aromatase inhibitor is other than fadrozole.
- Such human is a premenopausal woman.
- the present invention also provides the use of an aromatase inhibitor in the manufacture of a medicament for treating a sex steroid dependent cancer in a mammal, including humans, undergoing a simultaneous, separate or sequential treatment with a LHRH agonist or antagonist, and wherein, when the cancer is breast cancer, and a) the LHRH agonist is triptorelin, then the aromatase inhibitor is other than formestane, b) the LHRH agonist is goserelin, then the aromatase inhibitor is other than vorozole or formestane, or c) the LHRH agonist is leuprorelin, then the aromatase inhibitor is other than fadrozole.
- the invention also provides a product containing an aromatase inhibitor and a LHRH agonist or antagonist as a combined preparation for simultaneous, separate or sequential use in treating sex steroid dependent cancers, and wherein, when the cancer is breast cancer, and a) the
- LHRH agonist is triptorelin, then the aromatase inhibitor is other than formestane, b) the
- LHRH agonist is goserelin, then the aromatase inhibitor is other than vorozole or formestane, or c) the LHRH agonist is leuprorelin, then the aromatase inhibitor is other than fadrozole.
- the estrogen-dependent cancers that can by treated by the combined therapy method provided by the present invention are cancers known in the art as "sex steroid dependent cancers". Examples of such cancers are testicular cancer, prostate cancer, ovarian cancer, pancreatic cancer, uterine cancer, celomic epithelial carcinoma, germ cell ovarian cancer, fallopian tube ovarian cancer, breast cancer and lung cancer.
- such cancers are prostate cancer, ovarian cancer and breast cancer, in particular breast cancer in a premenopausal woman.
- aromatase inhibitors according to the invention are exemestane, formestane, fadrozole, letrozole, vorozole and anastrozole, preferably exemestane, anastrozole and letrozole, in particular exemestane.
- aromatase inhibitor is meant to comprise both a single aromatase inhibitor or a mixture of two or more, preferably two, aromatase inhibitors as defined above.
- the single aromatase inhibitor, or one of the component of the mixture is exemestane.
- LHRH agonists according to the invention are, e.g., leuprorelin, deslorelin, triptorelin, buserelin, nafarelin, goserelin, avorelin, histerelin, compound PTL 03001
- LHRH agonists are triptorelin and goserelin, or a pharmaceutically acceptable salt thereof, in particular triptorelin or a pharmaceutically acceptable salt thereof.
- LHRH antagonists are e.g. cetrorelix, abarelix, ramorelix, teverelix, ganirelix, compounds A 75998 (Acetyl-D-(2-naphthyl)alanyl-D-(4- chlorophenyl)alanyl-D-(3- ⁇ yridyl)alanyl-seryl-(N-methyl)tyrosyl-N6-(nicotinoyl)-D-lysyl- leucyl-N6-(isopropyl)lysyl-propyl-D-alaninamide) and A 84861 (Tetrahydrofuran-2-(S)- ylcarbonyl-glycyl-D-(2-naphthyl)alanyl-D-(4-cholro)phenylalanyl-D-(3-pyridyl)-alanyl-L-(N
- the inventors of the present invention have also found that treatment of the above mentioned sex steroid-dependent disorders by combined administration of a therapeutically effective amount of an aromatase inhibitor and a therapeutically effective amount of a LHRH agonist or antagonist, can produce a therapeutic effect which is greater than that obtainable by single administration of a therapeutically effective amount of sole LHRH agonist or antagonist. Most importantly, they have found that such newly obtained therapeutic effect is not paralleled by the toxic effects, otherwise caused by single administration of either therapeutically effective amounts of an aromatase inhibitor or, of the LHRH agonist or antagonist.
- treating means in particular “controlling the growth” of the neoplasm, namely slowing, interrupting, arresting, stopping or reversing the neoplasm formation and it does not necessarily indicate a total elimination of the neoplasm.
- the aromatase inhibitor and the LHRH agonist or antagonist can be administered in any form or mode which makes the compounds bioavailable in effective amounts, including oral and parenteral routes.
- admimstered or “administering” as used herein is meant any acceptable manner of administering a drug to a patient which is medically acceptable including parenteral and oral administration.
- parenteral is meant intravenous, subcutaneous, intradermal or intramuscular administration.
- Oral administration includes administering one or both of the constituents of the combined preparation in a suitable oral form such as, e.g., tablets, capsules, suspensions, solutions, emulsions, powders, syrups and the like.
- a suitable oral form such as, e.g., tablets, capsules, suspensions, solutions, emulsions, powders, syrups and the like.
- the actual preferred method and order of administration of the combined preparations of the invention can vary according to, inter alia, the particular pharmaceutical formulation of the aromatase inhibitor being utilized, the particular pharmaceutical formulation of the LHRH agonist or antagonist being utilized, the particular sex steroid-dependent cancer to be treated and the particular patient being treated.
- the term "close in time” means that in the combined method of treatment according to the subject invention, the aromatase inhibitor can be admimstered simultaneously with the LHRH agonist or antagonist or the compounds can be administered sequentially, in either order.
- the compounds are administered in such a way that both inhibition of hormone output of mammal's testis or ovaries and inhibition of aromatase enzyme are contemporaneously provided, and thus a therapeutically useful effect is achieved.
- Dosage The dosage ranges for the administration of the combined preparation can vary with the age, condition and extent of the disease in the patient and can be determined by one of skill in the art.
- the dosage regimen must therefore be tailored to the particular of the patient's conditions, response and associated treatments in a manner which is conventional for any therapy, and can be adjusted in response to changes in conditions and/or in light of other clinical conditions.
- An effective amount of an aromatase inhibitor antitumor agent can vary from about 0.5 to about 500 mg per dose 1-2 times a day.
- Fadrozole can be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2 mg.
- Letrozole for example, can be admimstered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2.5 mg.
- Formestane for example, can be administered parenterally in a dosage range varying from about 250 to about 500 mg, and particularly, from about 250 to about 300 mg.
- Anastrozole for example, can be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2 mg.
- Exemestane for instance can be administered orally in a dosage range varying from about 5 mg daily to about 600 mg daily, in particular from about 10 to about 50, more particularly from about 10 to about 25 mg daily, or parenterally in a dosage ranging from about 50 to about 500 mg per injection.
- An effective amount of LHRH agonist or antagonist is in general the one commonly used in therapy for such compounds.
- Goserelin can be administered as goserelin acetate by subcutaneous administration of slow release goserelin at a dosage from about 3 to about 12 mg.
- Triptorelin can be administered for instance as triptorelin pamaote by intramuscular administration in the form of a depot formulation at a dosage from about 3 to about 20 mg, in such a way that there is an interval of about 1, 2, 3 or 4 months between each administration.
- triptorelin pamoate can be administered intramuscularly in the form of microparticles as described in US Pat. No. 5,225,205 and US Pat. No. 5,776,885, and more specifically as 1- month depot formulation 3.75 mg.
- abarelix can be administered as single intramuscular administration of slow release abarelix 10 to 200 mg every 2 weeks or every month.
- the invention provides a method of treating a sex steroid dependent cancer selected from ovarian and breast cancer in a pre-menopausal woman in need of such treatment, comprising administering substantially simultaneously to said woman exemestane and triptorelin or a pharmaceutically acceptable salt thereof, in amounts and close in time sufficient to achieve a therapeutically useful effect.
- substantially simultaneous means that exemestane and triptorelin are administered in such a way that both inhibition of hormone out-put of her ovaries and inhibition of aromatase enzyme are contemporaneously provided, and thus a therapeutically useful effect is achieved.
- exemestane in the manufacture of a medicament for treating a sex steroid dependent cancer selected from ovarian and breast cancer in premenopausal woman, undergoing a substantially simultaneous treatment with triptorelin or a pharmaceutically acceptable salt thereof.
- breast cancer is treated.
- triptorelin pamoate salt are administered substantially simultaneously, as herein described, to achieve a therapeutically useful effect.
- triptorelin pamoate can be administered as a sustained release formulation, in such a way that there is an interval from about 1 to 4 months between each administration, e.g. in the form of 1 month depot 3.75 mg formulation, as described in US Pat. No. 5,225,205 and US Pat. No. 5,776,885.
- Exemestane can be administered parenterally at a dosage ranging from about 50 to about 500 mg per injection, or orally at a dosage from about 10 to about 25 mg daily.
- kits or single packages containing the pharmaceutical compositions useful for the combination treatment of the selected sex steroid- dependent cancers discussed above.
- the kits or packages can also contain instructions to use the pharmaceutical compositions in accordance with the present invention.
- a kit according to the present invention provides an exemestane 25 mg oral or 50-500 mg parenteral composition and a triptorelin 1 month depot formulation 3.75 mg.
- a pharmaceutical composition for intramuscular administration containing triptorelin pamoate in the form of a depot formulation can be prepared as described in US Pat. No. 5,225,205 and US Pat. No. 5,776,885.
- a pharmaceutical composition containing exemestane can be prepared, ple, according to US Pat. No. 4,808,616.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a combination therapy for treating estrogen dependent cancers in susceptible mammals, including humans, comprising the steps of inhibiting hormone output of their testis or ovaries, respectively, and administering to said mammal at least one aromatase inhibitor.
Description
COMBINATION THERAPY FOR ESTROGEN-DEPENDENT DISORDERS
Field of the invention
The present invention relates to a combination therapy for treating estrogen dependent cancers in susceptible mammals, including humans, comprising the steps of inhibiting hormone output of their testis or ovaries, respectively, and administering to said mammal at least one aromatase inhibitor.
Background of the invention
Various investigators have been studying hormone dependent breast and endometrial cancer. A known form of endocrine therapy in pre-menopausal women is oophorectomy, most commonly performed by surgery or irradiation, two procedures giving irreversible castration. A reversible form oophorectomy of has been achieved by utilizing Luteinizing Hormone Releasing Hormone agonists ("LHRH agonists") which, following inhibition of secretion of Luteinizing Hormone ("LH") by the pituitary gland, decrease serum estrogens to castrated levels (Nicholson et al, Brit. J. Cancer 39, 268-273, 1979).
Several studies show that treatment of pre-menopausal breast cancer patients with LHRH agonists induces responses comparable to those achieved with other forms of castration (Klijn et al., J. Steroid Biochem. 20, 1381, 1984; Manni et al., Endocr. Rev. 7: 89-94; 1986).
U.S. Pat. No. 4,775,660 relates to the treatment of female breast cancer by use of a combination therapy comprising administering an antiandrogen and an antiestrogen to a female after the hormone output of her ovaries has been blocked by chemical or surgical means. U.S. Pat. No. 4,775,661 relates to the treatment of female breast cancer by use of a therapy comprising administering to a female, after the hormone output of her ovaries has been blocked by chemical or surgical means, an antiandrogen and optionally an inhibitor of sex steroid biosynthesis.
U.S. Pat. No. 4,760,053 describes the treatment of selected sex steroid dependent cancers which combines a LHRH agonist and/or an antiandrogen and/or an antiestrogen and/or at least one inhibitor of sex steroid biosynthesis.
In U.S. Pat. No. 4,472,382 it is disclosed that prostatic adenocarcinoma, benign prostatic hypertrophy and hormone-dependent mammary tumors may be treated with various LH-RH
agonists and that prostate adenocarcinoma and benign hypertrophy may be treated by use of various LHRH agonists and an antiandrogen.
U.S. Pat. No. 5,550,107 relates to a treatment of female breast and endometrial cancer by use of a therapy comprising administering to a female after the hormone output of the ovaries has been blocked an antiestrogen and at least one compound selected, e.g., from an androgen, a progestin, at least one inhibitor of sex steroid biosynthesis and one inhibitor of prolactin secretion.
Some clinical improvement in pre-menopausal women with breast cancer by use of three LHRH agonists, goserelin, buserelin and leuprolide, is also reported by C.W. Taylor, "Multicenter randomized clinical trial of goserelin vs. surgical ovariectomy in premenopausal patients with receptor positive breast cancer" (J. Clin. One. 1998 (16): 994-999), H. A. Harvey et al. "LH-RH analogs in the treatment of human breast cancer", LHRH and its Analogs - A new Class of contraceptive and therapeutic Agents (B. H. Nickery and J. J. Nestor, J., and E. S.
E. Hafez, eds) Lancaster, MTP Press, (1984) and the J. G. M. Klijn et al, "Treatment with luteinizing hormone-relating hormone analogue (Buserelin) in premenopausal patients with metastatic breast cancer", Lancet 1, 1213-1216 (1982).
Stein R.C. et al. in British Journal of Cancer: 62, 679-683 (1990) describe the clinical and endocrine effects of 4-hydroxyandrostenedione (formestane) alone and in combination with goserelin in premenopausal woman with breast cancer. Celio L. et al. in European Journal of Cancer: S 155 , 691 (17 September 1997) and in Anticancer Research: 19, 2261-268 (1999) describe a study in premenopausal women with breast cancer by treatment with triptorelin and
4-hydroxyandrostenedione. Dowsett M. et al. in Breast Cancer Research and Treatment: 56, 24-
35 (1999) describe a combined treatment with vorozole and goserelin of breast cancer in premenopausal women. Tsuchiya N. et al. in International Journal of Clinical Oncology: (200) 5: 183-187 describe the effects of fadrazole and leuprorelin acetate on cell proliferation in a human breast cancer cell line.
It is an object of the present invention to provide a method for treating estrogen dependent cancers in mammals, in particular sex steroid dependent cancers, said method being not as invasive as surgery.
Detailed description of the invention
The invention provides a method for treating an sex-steroid dependent cancer in a mammal in need of such treatment, including humans, comprising administering
simultaneously, separately or sequentially to said mammal an aromatase inhibitor and a
LHRH agonist or antagonist, in amounts and close in time sufficient to achieve a therapeutically useful effect, and wherein, when the cancer is breast cancer, and a) the LHRH agonist is triptorelin, then the aromatase inhibitor is other than formestane, b) the LHRH agonist is goserelin, then the aromatase inhibitor is other than vorozole or formestane, or c) the
LHRH agonist is leuprorelin, then the aromatase inhibitor is other than fadrozole.
Preferably such human is a premenopausal woman.
The present invention also provides the use of an aromatase inhibitor in the manufacture of a medicament for treating a sex steroid dependent cancer in a mammal, including humans, undergoing a simultaneous, separate or sequential treatment with a LHRH agonist or antagonist, and wherein, when the cancer is breast cancer, and a) the LHRH agonist is triptorelin, then the aromatase inhibitor is other than formestane, b) the LHRH agonist is goserelin, then the aromatase inhibitor is other than vorozole or formestane, or c) the LHRH agonist is leuprorelin, then the aromatase inhibitor is other than fadrozole. The invention also provides a product containing an aromatase inhibitor and a LHRH agonist or antagonist as a combined preparation for simultaneous, separate or sequential use in treating sex steroid dependent cancers, and wherein, when the cancer is breast cancer, and a) the
LHRH agonist is triptorelin, then the aromatase inhibitor is other than formestane, b) the
LHRH agonist is goserelin, then the aromatase inhibitor is other than vorozole or formestane, or c) the LHRH agonist is leuprorelin, then the aromatase inhibitor is other than fadrozole.
The estrogen-dependent cancers that can by treated by the combined therapy method provided by the present invention are cancers known in the art as "sex steroid dependent cancers". Examples of such cancers are testicular cancer, prostate cancer, ovarian cancer, pancreatic cancer, uterine cancer, celomic epithelial carcinoma, germ cell ovarian cancer, fallopian tube ovarian cancer, breast cancer and lung cancer.
In one embodiment of the invention, such cancers are prostate cancer, ovarian cancer and breast cancer, in particular breast cancer in a premenopausal woman.
Examples of aromatase inhibitors according to the invention are exemestane, formestane, fadrozole, letrozole, vorozole and anastrozole, preferably exemestane, anastrozole and letrozole, in particular exemestane.
The term "aromatase inhibitor" is meant to comprise both a single aromatase inhibitor or a mixture of two or more, preferably two, aromatase inhibitors as defined above. Preferably the single aromatase inhibitor, or one of the component of the mixture, is exemestane.
Examples of LHRH agonists according to the invention are, e.g., leuprorelin, deslorelin, triptorelin, buserelin, nafarelin, goserelin, avorelin, histerelin, compound PTL 03001
(5-oxo-L-propyl-L-liistidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-N- ethyl-L-prolinamide) (Peptech), compound AN 207 (6-[N6-[5-[2-[ 1, 2,3,4,6, 11-hexahydro- 2,5, 12-trihydroxy-7-mehoxy-6, 11 -dioxo-4-[[2,3 ,6-trideoxy-3 -(2,3 -dihydro- 1 H-pyrrol- 1 -yl)α-L- lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-l,5-dioxopentyl]-D-lysine]-,(2S-cis)-) (ASTA
Medica Inc.), compound AN 238 L-threoninamide, N-[5-[2-[(2S,4S)-l,2,3,4,6,ll-hexahydro-
2,5,12-trihydroxy-7-methoxy-6,l l-dioxo-4-[[2,3,6-trideoxy-3-(2,3-dihydro-lH-pyrrl-l-yl)α-L- lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethoxy]-l,5-dioxopentyl]-D-phenylalanyl-L- cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2 7)-disulfide (ASTA Medica Inc.) and compound SPD 424 (LHRH-hydrogel implant) (Shire Pharmaceuticals Group), or a pharmaceutically acceptable salt thereof.
In one embodiment of the invention, LHRH agonists are triptorelin and goserelin, or a pharmaceutically acceptable salt thereof, in particular triptorelin or a pharmaceutically acceptable salt thereof.
Examples of LHRH antagonists, according to the invention, are e.g. cetrorelix, abarelix, ramorelix, teverelix, ganirelix, compounds A 75998 (Acetyl-D-(2-naphthyl)alanyl-D-(4- chlorophenyl)alanyl-D-(3-ρyridyl)alanyl-seryl-(N-methyl)tyrosyl-N6-(nicotinoyl)-D-lysyl- leucyl-N6-(isopropyl)lysyl-propyl-D-alaninamide) and A 84861 (Tetrahydrofuran-2-(S)- ylcarbonyl-glycyl-D-(2-naphthyl)alanyl-D-(4-cholro)phenylalanyl-D-(3-pyridyl)-alanyl-L-(N- methyl)tyrosyl-D-[N6-(3-pyridylcarbonyl)]lysyl-L-leucyl-L-(N6-isopropyl)lysyl-L-propyl-D- alanylamide)(Abbot Labs.), GnRH immunogen (Aphton Co.), compound T 98475 (Isopropyl 3- (N-be----2yl-N-methyl-uι inomethyl)-7-(2,6-difluorobenzyl)-4,7-dihydro-2-(4- isobutyrylaminophenyl)-4-oxothieno[2,3-bpyridine-5-carboxylate hydrochloride) (Takeda), and compound MI 1544 (Acetyl-D-tryptophyl-D-cyclopropyl-alanyl-D-tryptophyl-L-seryl-L- tyrosyl-D-lysyl-L-leucyl-L-arginyl-L-propyl-D-alaninamide), or a pharmaceutically acceptable salt thereof. An exemplary LHRH antagonist is abarelix or a pharmaceutically acceptable salt thereof.
The inventors of the present invention have also found that treatment of the above mentioned sex steroid-dependent disorders by combined administration of a therapeutically effective amount of an aromatase inhibitor and a therapeutically effective amount of a LHRH agonist or antagonist, can produce a therapeutic effect which is greater than that obtainable by single administration of a therapeutically effective amount of sole LHRH agonist or antagonist.
Most importantly, they have found that such newly obtained therapeutic effect is not paralleled by the toxic effects, otherwise caused by single administration of either therapeutically effective amounts of an aromatase inhibitor or, of the LHRH agonist or antagonist. As used herein, the term "treating" means in particular "controlling the growth" of the neoplasm, namely slowing, interrupting, arresting, stopping or reversing the neoplasm formation and it does not necessarily indicate a total elimination of the neoplasm.
Therefore, the term "therapeutically useful effect", besides slowing, interrupting, arresting, stopping or reversing, the neoplasm formation, simply also means that the life expectancy of an individual affected with a cancer will be increased, that one or more of the symptoms of the disease will be reduced and/or that quality of life will be enhanced.
Method and Administration
In effecting treatment of a patient in a therapy method according to the invention, the aromatase inhibitor and the LHRH agonist or antagonist can be administered in any form or mode which makes the compounds bioavailable in effective amounts, including oral and parenteral routes.
By the term "admimstered" or "administering" as used herein is meant any acceptable manner of administering a drug to a patient which is medically acceptable including parenteral and oral administration.
By "parenteral" is meant intravenous, subcutaneous, intradermal or intramuscular administration.
Oral administration includes administering one or both of the constituents of the combined preparation in a suitable oral form such as, e.g., tablets, capsules, suspensions, solutions, emulsions, powders, syrups and the like.
The actual preferred method and order of administration of the combined preparations of the invention can vary according to, inter alia, the particular pharmaceutical formulation of the aromatase inhibitor being utilized, the particular pharmaceutical formulation of the LHRH agonist or antagonist being utilized, the particular sex steroid-dependent cancer to be treated and the particular patient being treated.
The term "close in time" means that in the combined method of treatment according to the subject invention, the aromatase inhibitor can be admimstered simultaneously with the LHRH agonist or antagonist or the compounds can be administered sequentially, in either order. However, the compounds are administered in such a way that both inhibition of hormone output
of mammal's testis or ovaries and inhibition of aromatase enzyme are contemporaneously provided, and thus a therapeutically useful effect is achieved.
Dosage The dosage ranges for the administration of the combined preparation can vary with the age, condition and extent of the disease in the patient and can be determined by one of skill in the art.
The dosage regimen must therefore be tailored to the particular of the patient's conditions, response and associated treatments in a manner which is conventional for any therapy, and can be adjusted in response to changes in conditions and/or in light of other clinical conditions.
An effective amount of an aromatase inhibitor antitumor agent can vary from about 0.5 to about 500 mg per dose 1-2 times a day.
Fadrozole, for example, can be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2 mg. Letrozole, for example, can be admimstered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2.5 mg. Formestane, for example, can be administered parenterally in a dosage range varying from about 250 to about 500 mg, and particularly, from about 250 to about 300 mg. Anastrozole, for example, can be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2 mg. Exemestane for instance can be administered orally in a dosage range varying from about 5 mg daily to about 600 mg daily, in particular from about 10 to about 50, more particularly from about 10 to about 25 mg daily, or parenterally in a dosage ranging from about 50 to about 500 mg per injection. An effective amount of LHRH agonist or antagonist is in general the one commonly used in therapy for such compounds. Goserelin can be administered as goserelin acetate by subcutaneous administration of slow release goserelin at a dosage from about 3 to about 12 mg. Triptorelin can be administered for instance as triptorelin pamaote by intramuscular administration in the form of a depot formulation at a dosage from about 3 to about 20 mg, in such a way that there is an interval of about 1, 2, 3 or 4 months between each administration. In particular triptorelin pamoate can be administered intramuscularly in the form of microparticles as described in US Pat. No. 5,225,205 and US Pat. No. 5,776,885, and more specifically as 1- month depot formulation 3.75 mg. For instance, abarelix can be administered as single
intramuscular administration of slow release abarelix 10 to 200 mg every 2 weeks or every month.
The invention provides a method of treating a sex steroid dependent cancer selected from ovarian and breast cancer in a pre-menopausal woman in need of such treatment, comprising administering substantially simultaneously to said woman exemestane and triptorelin or a pharmaceutically acceptable salt thereof, in amounts and close in time sufficient to achieve a therapeutically useful effect.
The term "substantially simultaneous" means that exemestane and triptorelin are administered in such a way that both inhibition of hormone out-put of her ovaries and inhibition of aromatase enzyme are contemporaneously provided, and thus a therapeutically useful effect is achieved.
As a further embodiment of the invention it is here also provided the use of exemestane in the manufacture of a medicament for treating a sex steroid dependent cancer selected from ovarian and breast cancer in premenopausal woman, undergoing a substantially simultaneous treatment with triptorelin or a pharmaceutically acceptable salt thereof. In one embodiment of the invention breast cancer is treated.
In one embodiment of the invention, exemestane and triptorelin, in particular as pamoate salt, are administered substantially simultaneously, as herein described, to achieve a therapeutically useful effect. In particular, triptorelin pamoate can be administered as a sustained release formulation, in such a way that there is an interval from about 1 to 4 months between each administration, e.g. in the form of 1 month depot 3.75 mg formulation, as described in US Pat. No. 5,225,205 and US Pat. No. 5,776,885. Exemestane can be administered parenterally at a dosage ranging from about 50 to about 500 mg per injection, or orally at a dosage from about 10 to about 25 mg daily.
As stated above, the invention also provides kits or single packages containing the pharmaceutical compositions useful for the combination treatment of the selected sex steroid- dependent cancers discussed above. The kits or packages can also contain instructions to use the pharmaceutical compositions in accordance with the present invention. As an example a kit according to the present invention provides an exemestane 25 mg oral or 50-500 mg parenteral composition and a triptorelin 1 month depot formulation 3.75 mg. A pharmaceutical composition for intramuscular administration containing triptorelin pamoate in the form of a depot formulation can be prepared as described in US Pat. No. 5,225,205 and US Pat. No. 5,776,885.
A pharmaceutical composition containing exemestane can be prepared, ple, according to US Pat. No. 4,808,616.
All references cited in this disclosure are incorporated herein by reference.
Claims
1. A method for treating a sex steroid dependent cancer in a mammal in need of such treatment, comprising administering simultaneously, separately or sequentially to said mammal an aromatase inhibitor and a LHRH agonist or antagonist, in amounts sufficient to achieve a therapeutically useful effect and wherein, when the cancer is breast cancer, and a) the LHRH agonist is triptorelin, then the aromatase inhibitor is other than formestane, b) the LHRH agonist is goserelin, then the aromatase inhibitor is other than vorozole or formestane, or c) the LHRH agonist is leuprorelin, then the aromatase inhibitor is other than fadrozole.
2. The method according to claim 1, wherein the sex steroid dependent cancer is selected from the group consisting of testicular cancer, prostate cancer, ovarian cancer, pancreatic cancer, uterine cancer, celomic epithelial carcinoma, germ cell ovarian cancer, fallopian tube ovarian cancer, breast cancer and lung cancer.
3. The method according to claim 1, wherein the estrogen-dependent cancer is breast cancer in a premenopausal woman.
4. The method of claim 1, wherein the mammal is a human.
5. The method according to claim 1, wherein the aromatase inhibitor is selected from the group consisting of exemestane, formestane, fadrozole, letrozole, vorozole, anastrozole, and a mixture of two or more of them.
6. The method according to claim 1 , wherein the aromatase inhibitor is exemestane.
7. The method according to claim 5, wherein when administered orally, the amount of aromatase inhibitor exemestane is from about 5 to about 600 mg, fadrozole from about 0.5 to about 10 mg, letrozole from about 0.5 to about 10 mg, and anastrozole from about 0.5 to about 10 mg.
8. The method according to claim 5, wherein when administered parenterally, the amount of aromatase inhibitor exemestane is from about 5 to about 500 mg, and formestane is from about 250 to about 500 mg.
9. The method according to claim 1, wherein the LHRH agonist is selected from the group consisting of leuprorelin, deslorelin, triptorelin, buserelin, nafarelin, goserelin, avorelin, histerelin, compound PTL 03001 (5-oxo-L-propyl-L-histidyl-L-tryptophyl-L-seryl-L- tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide), compound AN 207 (6- [N6-[5-[2-[l,2,3,4,6,ll-hexahydro-2,5,12-trihydroxy-7-mehoxy-6,ll-dioxo-4-[[2,3,6- trideoxy-3-(2,3-dihydro-lH-pyrrol-l-yl)α-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-l,5- dioxopentyl]-D-lysine]-,(2S-cis)-), compound AN 238 (L-threoninamide, N-[5-[2-[(2S,4S 1,2,3,4,6,1 l-hexahydro-2,5,12-trihydroxy-7-methoxy-6,l l-dioxo-4-[[2,3,6-trideoxy-3-(2,3- dihydro- 1 H-pyrrl- 1 -yl)α-L-lyxo-hexopyranosyl] oxy] -2-naphthacenyl] -2-oxoethoxy] -1,5- dioxopentyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L- cysteinyl-, cyclic (2 7)-disulfide), compound SPD 424 (LHRH-hydrogel implant), and a pharmaceutically acceptable salt thereof.
10. The method according to claim 1, wherein the LHRH agonist is selected from triptorelin, goserelin, and a pharmaceutically acceptable salt thereof.
11. The method according to claim 1, wherein the LHRH agonist is triptorelin or a pharmaceutically acceptable salt thereof.
12. The method according to claim 1, wherein the LHRH agonist is triptorelin pamoate.
13. The method according to claim 1, wherein the LHRH agonist triptorelin pamoate is in the form of a depot formulation, at a dosage from about 3 to about 20 mg.
14. The method according to claim 13, wherein the LHRH agonist triptorelin pamoate is in the form of a 1 month depot foπnulation 3.75 mg.
15. The method according to claim 1, wherein the LHRH antagonist is selected from the group consisting of cetrorelix, abarelix, ramorelix, teverelix, ganirelix, compound A 75998 (Acetyl-D-(2-naphthyl)alanyl-D-(4-chloroρhenyl)alanyl-D-(3-ρyridyl)alanyl-seryl-(N- methyl)tyrosyl-N6-(nicotinoyl)-D-lysyl- leucyl-N6-(isopropyl)lysyl-propyl-D- alaninamide), compound A 84861 (Tetrahydrofuran-2-(S)-ylcarbonyl-glycyl-D-(2- naphthyl)alanyl-D-(4-cholro)phenylalanyl-D-(3-pyridyl)-alanyl-L-(N-methyl)tyrosyl-D-
[N6-(3-ρyridylcarbonyl)]lysyl-L-leucyl-L-(N6-isopropyl)lysyl-L-propyl-D-alanylamide),
GnRH immunogen, compound T 98475 (Isopropyl 3-(N-benzyl-N-methylaminomethyl)-7-
(2,6-difluorobenzyl)-4,7-dihydro-2-(4-isobutyrylaminophenyl)-4-oxothieno[2,3-bpyridine-
5-carboxylate hydrochloride), compound MI 1544 (Acetyl-D-tryptophyl-D-cyclopropyl- alanyl-D-tryptophyl-L-seryl-L-tyrosyl-D-lysyl-L-leucyl-L-arginyl-L-propyl-D- alaninamide), and a pharmaceutically acceptable salt thereof.
16. A method of treating a sex steroid dependent cancer selected from ovarian and breast cancer in a pre-menopausal woman in need of such treatment, comprising administering to said woman exemestane and triptorelin or a pharmaceutically acceptable salt thereof, in amounts sufficient to achieve a therapeutically useful effect.
17. The method according to claim 16, wherein both inhibition of hormone out-put of the women's ovaries and inhibition/inactivation of aromatase enzyme are contemporaneously provided, and thus a therapeutically useful effect is achieved.
18. The method according to claim 16, wherein the estrogen dependent cancer is breast cancer.
19. The method according to claim 16, wherein triptorelin is in the form of triptorelin pamoate salt.
20. The method according to claim 16, wherein triptorelin pamoate is in the form of a depot formulation.
21. The method according to claim 16, wherein triptorelin pamoate is in the form of 1 month depot formulation 3.75 mg.
22. The method according to claim 16, wherein about 5 to 600 mg/day of exemestane is administered orally.
23. The method according to claim 16, wherein about 10 to 500 mg/day of exemestane is administered orally.
24. The method according to claim 16, wherein about 25 mg/day of exemestane is administered orally.
25. The method according to claim 16, wherein about 50 to 500 mg/day of exemestane is administered parenterally.
26. Use of an aromatase inhibitor in the manufacture of a medicament for treating a sex steroid dependent cancer in a mammal undergoing a simultaneous, separate or sequential treatment with a LHRH agonist or antagonist, and wherein, when the cancer is breast cancer, and a) the LHRH agonist is triptorelin, then the aromatase inhibitor is other than formestane, b) the LHRH agonist is goserelin, then the aromatase inhibitor is other than vorozole or formestane, or c) the LHRH agonist is leuprorelin, then the aromatase inhibitor is other than fadrozole.
27. Use according to claim 26, wherein the mammal is a human.
28. Use according to claim 26, wherein the aromatase inhibitor is exemestane, the LHRH agonist is triptorelin and the sex steroid dependent cancers are ovarian and breast cancers.
29. Product containing an aromatase inhibitor and a LHRH agonist or antagonist as a combined preparation for simultaneous, separate or sequential use in treating sex-dependent cancers, and wherein, when the cancer is breast cancer, and a) the LHRH agonist is triptorelin, then the aromatase inhibitor is other than formestane, b) the LHRH agonist is goserelin, then the aromatase inhibitor is other than vorozole or formestane, or c) the LHRH agonist is leuprorelin, then the aromatase inhibitor is other than fadrozole.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71460500A | 2000-11-16 | 2000-11-16 | |
US714605 | 2000-11-16 | ||
PCT/US2001/043847 WO2002039995A2 (en) | 2000-11-16 | 2001-11-06 | Combination therapy for estrogen-dependent disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1341549A2 true EP1341549A2 (en) | 2003-09-10 |
Family
ID=24870727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01990699A Withdrawn EP1341549A2 (en) | 2000-11-16 | 2001-11-06 | Combination therapy for estrogen-dependent disorders |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1341549A2 (en) |
JP (1) | JP2004536022A (en) |
KR (1) | KR20030051828A (en) |
CN (1) | CN1498112A (en) |
AU (1) | AU2002230464A1 (en) |
BR (1) | BR0115423A (en) |
CA (1) | CA2428249A1 (en) |
CZ (1) | CZ20031349A3 (en) |
EA (1) | EA200300572A1 (en) |
IL (1) | IL155817A0 (en) |
MX (1) | MXPA03004195A (en) |
NO (1) | NO20032206L (en) |
NZ (1) | NZ525720A (en) |
PL (1) | PL365904A1 (en) |
WO (1) | WO2002039995A2 (en) |
ZA (1) | ZA200303669B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9050378B2 (en) | 2003-12-10 | 2015-06-09 | Board Of Regents, The University Of Texas System | N2S2 chelate-targeting ligand conjugates |
GB0506759D0 (en) * | 2005-04-02 | 2005-05-11 | Medical Res Council | Combination treatment methods |
EP1891964A1 (en) * | 2006-08-08 | 2008-02-27 | AEterna Zentaris GmbH | Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits |
US10925977B2 (en) | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
JP2010524996A (en) * | 2007-04-23 | 2010-07-22 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Combination of progesterone receptor antagonists with lutein hormone releasing hormone agonists and antagonists for use in BRCA mediated diseases |
CN101775054B (en) * | 2010-02-05 | 2012-12-26 | 常州佳尔科药业集团有限公司 | Synthesis method of 4-hydroxyl-4-alkene-3-ketone steroide compound |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9911582D0 (en) * | 1999-05-18 | 1999-07-21 | Pharmacia & Upjohn Spa | Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound |
GB9930839D0 (en) * | 1999-12-30 | 2000-02-16 | Pharmacia & Upjohn Spa | Process for treating gynecomastia |
-
2001
- 2001-11-06 EP EP01990699A patent/EP1341549A2/en not_active Withdrawn
- 2001-11-06 CZ CZ20031349A patent/CZ20031349A3/en unknown
- 2001-11-06 IL IL15581701A patent/IL155817A0/en unknown
- 2001-11-06 CN CNA018189385A patent/CN1498112A/en active Pending
- 2001-11-06 AU AU2002230464A patent/AU2002230464A1/en not_active Abandoned
- 2001-11-06 PL PL01365904A patent/PL365904A1/en not_active Application Discontinuation
- 2001-11-06 MX MXPA03004195A patent/MXPA03004195A/en unknown
- 2001-11-06 EA EA200300572A patent/EA200300572A1/en unknown
- 2001-11-06 JP JP2002542370A patent/JP2004536022A/en active Pending
- 2001-11-06 CA CA002428249A patent/CA2428249A1/en not_active Abandoned
- 2001-11-06 KR KR10-2003-7006608A patent/KR20030051828A/en not_active Application Discontinuation
- 2001-11-06 NZ NZ525720A patent/NZ525720A/en unknown
- 2001-11-06 BR BR0115423-0A patent/BR0115423A/en not_active IP Right Cessation
- 2001-11-06 WO PCT/US2001/043847 patent/WO2002039995A2/en active Application Filing
-
2003
- 2003-05-13 ZA ZA200303669A patent/ZA200303669B/en unknown
- 2003-05-15 NO NO20032206A patent/NO20032206L/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO0239995A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002039995A9 (en) | 2003-02-06 |
EA200300572A1 (en) | 2004-06-24 |
NO20032206L (en) | 2003-07-15 |
NZ525720A (en) | 2006-12-22 |
MXPA03004195A (en) | 2003-09-22 |
WO2002039995A2 (en) | 2002-05-23 |
AU2002230464A1 (en) | 2002-05-27 |
IL155817A0 (en) | 2003-12-23 |
WO2002039995A3 (en) | 2003-05-01 |
ZA200303669B (en) | 2004-05-13 |
NO20032206D0 (en) | 2003-05-15 |
PL365904A1 (en) | 2005-01-10 |
CN1498112A (en) | 2004-05-19 |
BR0115423A (en) | 2005-12-13 |
CZ20031349A3 (en) | 2004-05-12 |
CA2428249A1 (en) | 2002-05-23 |
JP2004536022A (en) | 2004-12-02 |
KR20030051828A (en) | 2003-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Felberbaum et al. | Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. | |
Gonzalez-Barcena et al. | Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. | |
CZ291709B6 (en) | Medicament for treating ovarian estrogen dependent condition | |
US7309691B2 (en) | Combined pharmaceutical preparation containing LHRH-analogous substances and anti estrogens for treating gynaecological disorders | |
WO2000030674A1 (en) | Neuropeptide y y4 agents in the treatment of reproductive disorders | |
Griesinger et al. | GnRH-antagonists in reproductive medicine | |
WO2002039995A2 (en) | Combination therapy for estrogen-dependent disorders | |
Klijn | LH-RH agonists in the treatment of metastatic breast cancer: ten years’ experience | |
US5023234A (en) | Combination male breast cancer therapy | |
Kotlyar et al. | Eliminating hormones with orally active gonadotropin-releasing hormone antagonists | |
WO2002039996A2 (en) | Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists | |
RU2181598C2 (en) | Recovery of tonic secretion of ovarian estrogen for prolonged therapeutic schemes | |
US20040043938A1 (en) | Combination therapy for estrogen-dependent disorders | |
Savino et al. | GnRH analogs in gynecological oncology: a review | |
US20120004182A1 (en) | Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells | |
EP1029868A1 (en) | Hysteromyoma remedy containing dienogest as the active ingredient | |
Fluker | Gonadotropin-releasing hormone antagonists | |
LT4341B (en) | Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens | |
Forti | Clinicai applications of GnRH analogs | |
Adegoke et al. | GnRH Antagonists in the Treatment of Uterine Fibroids | |
KR100210472B1 (en) | Luteinizing hormone releasing hormone antagonist peptides | |
Engel et al. | Luteinizing hormone-releasing hormone antagonists in gynecology | |
HU199694B (en) | Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives | |
CN114903902A (en) | Application of GnRH receptor antagonist and androgen receptor antagonist in preparation of medicine for treating prostatic cancer | |
Foldesy et al. | Role of adrenal androgens in prostate regression in rats treated with an antiandrogen and an LHRH agonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030529 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PHARMACIA & UPJOHN COMPANY LLC |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080602 |